Is Fortress Biotech, Inc. overvalued or undervalued?

As of 10 May 2016, Fortress Biotech, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently overvalued given its negative performance metrics and ratios. Key ratios include a Price to Book Value of 2.66, an EV to EBIT of -0.29, and an EV to Sales of 0.49, which indicate significant financial distress.
In comparison to its peers, Fortress Biotech's P/E ratio is -0.5040, while Rezolute, Inc. has a P/E of -4.9009 and Assembly Biosciences, Inc. has a P/E of -3.2679. This suggests that Fortress is not only underperforming relative to its peers but also reflects a broader trend of negative valuation in the industry. The company's recent stock performance, with a year-to-date decline of 15.56% compared to a 2.44% rise in the S&P 500, further reinforces the conclusion that Fortress Biotech is overvalued.